Search Within

Sandra Misale

Formats
  1. Journal Article (8)
  2. Meeting Abstract (6)
  3. Editorial (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Sloan Kettering Institute Postdocs (17)
  2. Department of Medicine (11)
  3. Solid Tumor Oncology Division (11)
  4. Breast Medicine Service (10)
  5. GSK Faculty (10)
  6. Department of Pathology and Laboratory Medicine (9)

More Groups

People
  1. Rona Yaeger (8)
  2. Elisa De Stanchina (7)
  3. Neal Rosen (7)
  4. Bob Li (6)
  5. Alexander Drilon (5)
  6. Michael Berger (5)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (4)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (3)

More Years

Publications
  1. Cancer Discovery (5)
  2. Cancer Research (4)
  3. Clinical Cancer Research (1)
  4. Journal of Clinical Oncology (1)
  5. Molecular Cancer Research (1)
  6. Nature (1)

More Publications

Publishers
  1. American Association for Cancer Research (11)
  2. Nature Publishing Group (3)
  3. American Society of Clinical Oncology (1)
  4. Nature Research (1)
  5. Oxford University Press (1)

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combined RAF and MEK inhibition to treat activated non-V600 BRAF-altered advanced cancers
    Journal Article

    Rustgi, N.; Maria, A.; Toumbacaris, N.; Zhao, H.; Kargus, K.; Bryant, M.; Waksmundzki, A.; Aricescu, I.; Lefkowitz, R. A.; Li, B. T.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Molecular characterization of acquired resistance to KRAS(G12C)-EGFR inhibition in colorectal cancer
    Meeting Abstract

    Misale, S.
    Molecular Cancer Research (2023)

    Fulltext@MSK | Save
  • Molecular characterization of acquired resistance to KRAS(G12C)–EGFR inhibition in colorectal cancer
    Journal Article

    Yaeger, R.; Mezzadra, R.; Sinopoli, J.; Bian, Y.; Marasco, M.; Kaplun, E.; Gao, H.; Zhao, H. Y.; Paula, A. D. C.; Zhu, Y.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Expanding the reach of precision oncology by drugging all KRAS mutants
    Review

    Hofmann, M. H.; Gerlach, D.; Misale, S.; Petronczki, M.; Kraut, N.
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Resistance is futile with fourth-generation EGFR inhibitors
    Editorial

    Marasco, M.; Misale, S.
    Nature Cancer (2022)

    Fulltext@MSK | Save
  • Anatomic position determines oncogenic specificity in melanoma
    Journal Article

    Weiss, J. M.; Hunter, M. V.; Cruz, N. M.; Baggiolini, A.; Tagore, M.; Ma, Y.; Misale, S.; Marasco, M.; Simon-Vermot, T.; Campbell, N. R.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • KRAS(G12C) mutation is associated with increased risk of recurrence in surgically resected lung adenocarcinoma
    Journal Article

    Jones, G. D.; Caso, R.; Tan, K. S.; Mastrogiacomo, B.; Sanchez-Vega, F.; Liu, Y.; Connolly, J. G.; Murciano-Goroff, Y. R.; Bott, M. J.; Adusumilli, P. S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • TRK XDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Journal Article

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arruabarrena-Aristorena, A.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer
    Journal Article

    Amodio, V.; Yaeger, R.; Arcella, P.; Cancelliere, C.; Lamba, S.; Lorenzato, A.; Arena, S.; Montone, M.; Mussolin, B.; Bian, Y.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save